Magnetic seizure therapy by Magnetic stimulatorAntipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
Magnetic seizure therapy by Magnetic stimulator: The seizure is induced by Magnetic stimulator of MagPro MST(XP),MagVenture A/S, Farum, Denmark. It is administered in combinations with antipsychotic medications
Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc): It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.
Study summary
This trial aims to evaluate the efficacy and safety of Magnetic Seizure Therapy (MST) as an augmentation of antipsychotic medications for psychosis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria:
* (1) meets the diagnostic criteria for schizophrenia or other primary psychotic disorders according to DSM-5;
* (2) age range between 18 and 55 years;
* (3) Positive And Negative Syndrome Scale (PANSS) score≥60;
* (4) to provide informed consent.
Exclusion Criteria:
* (1) have a concomitant severe medical illness;
* (2) are pregnant or intend to get pregnant during the study;
* (3) have a history of DSM-5 diagnosis of substance dependence or abuse within the past three months;
* (4) history of traumatic brain injury (with a screening scale score of 7 or above);
* (5) history of poor response to electroconvulsive therapy or MST;
* (6) have probable dementia based on study investigator assessment; have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space occupying brain lesion, e.g., cerebral aneurysm;
* (7) presenting with a medical condition, medication, or laboratory anomaly deemed by the investigator to potentially induce psychotic symptoms, or significant cognitive impairment. (e.g., hypothyroidism with low TSH, rheumatoid arthritis requiring high dose prednisone, or Cushing's disease);
* (8) have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
* (9) a score of 18 or more on the 24-item Hamilton Depression Rating Scale (HAM-D);
* (10) needing ECT treatment immediately due to such dangerous symptoms as suicide, stupor or psychomotor agitation, etc.
Primary outcome measure(s)
Changes in Positive and Negative Symptom Scale (PANSS) — Baseline, 1 weeks, 2 weeks, 6 weeks measured by Positive and Negative Symptom Scale (PANSS)
Trial sites (2)
Facility
City
Region
Status
Shanghai Mental Health Center
Shanghai
Shanghai Municipality
Not Yet Recruiting
Shanghai Mental Health Center
Shanghai
Shanghai Municipality
Recruiting
More Shanghai Jiao Tong University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.